References

1. Moremen, K.W.; Tiemeyer, M.; Nairn, A.V. Vertebrate protein glycosylation: Diversity, synthesis and function. Nat Rev Mol Cell Biol 2012, 13, 448-462.
2. Tarp, M.A.; Clausen, H. Mucin-type o-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008, 1780, 546-563.
3. Tian, E.; Ten Hagen, K.G. Recent insights into the biological roles of mucin-type o-glycosylation. Glycoconj J 2009, 26, 325-334.
4. Tran, D.T.; Ten Hagen, K.G. Mucin-type o-glycosylation during development. J Biol Chem 2013, 288, 6921-6929.
5. Bennett, E.P.; Mandel, U.; Clausen, H.; Gerken, T.A.; Fritz, T.A.; Tabak, L.A. Control of mucin-type o-glycosylation: A classification of the polypeptide galnac-transferase gene family. Glycobiology 2012, 22, 736-756.
6. Ten Hagen, K.G.; Fritz, T.A.; Tabak, L.A. All in the family: The udp-galnac:Polypeptide n-acetylgalactosaminyltransferases. Glycobiology 2003, 13, 1R-16R.
7. Beaman, E.M.; Brooks, S.A. The extended ppgalnac-t family and their functional involvement in the metastatic cascade. Histol Histopathol 2014, 29, 293-304.
8. Wang, H.; Tachibana, K.; Zhang, Y.; Iwasaki, H.; Kameyama, A.; Cheng, L.; Guo, J.; Hiruma, T.; Togayachi, A.; Kudo, T., et al. Cloning and characterization of a novel udp-galnac:Polypeptide n-acetylgalactosaminyltransferase, pp-galnac-t14. Biochem Biophys Res Commun 2003, 300, 738-744.
9. Hagen, F.K.; Hazes, B.; Raffo, R.; deSa, D.; Tabak, L.A. Structure-function analysis of the udp-n-acetyl-d-galactosamine:Polypeptide n-acetylgalactosaminyltransferase. Essential residues lie in a predicted active site cleft resembling a lactose repressor fold. J Biol Chem 1999, 274, 6797-6803.
10. Unligil, U.M.; Zhou, S.; Yuwaraj, S.; Sarkar, M.; Schachter, H.; Rini, J.M. X-ray crystal structure of rabbit n-acetylglucosaminyltransferase i: Catalytic mechanism and a new protein superfamily. EMBO J 2000, 19, 5269-5280.
11. Wagner, K.W.; Punnoose, E.A.; Januario, T.; Lawrence, D.A.; Pitti, R.M.; Lancaster, K.; Lee, D.; von Goetz, M.; Yee, S.F.; Totpal, K., et al. Death-receptor o-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand apo2l/trail. Nat Med 2007, 13, 1070-1077.
12. Huanna, T.; Tao, Z.; Xiangfei, W.; Longfei, A.; Yuanyuan, X.; Jianhua, W.; Cuifang, Z.; Manjing, J.; Wenjing, C.; Shaochuan, Q., et al. Galnt14 mediates tumor invasion and migration in breast cancer cell mcf-7. Mol Carcinog 2015, 54, 1159-1171.
13. Song, K.H.; Park, M.S.; Nandu, T.S.; Gadad, S.; Kim, S.C.; Kim, M.Y. Galnt14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment. Nat Commun 2016, 7, 13796.
14. Wang, R.; Yu, C.; Zhao, D.; Wu, M.; Yang, Z. The mucin-type glycosylating enzyme polypeptide n-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. Oncol Rep 2013, 30, 667-676.
15. Kwon, O.S.; Oh, E.; Park, J.R.; Lee, J.S.; Bae, G.Y.; Koo, J.H.; Kim, H.; Choi, Y.L.; Choi, Y.S.; Kim, J., et al. Galnac-t14 promotes metastasis through wnt dependent hoxb9 expression in lung adenocarcinoma. Oncotarget 2015, 6, 41916-41928.
16. Shan, J.; Liu, Y.; Wang, Y.; Li, Y.; Yu, X.; Wu, C. Galnt14 involves the regulation of multidrug resistance in breast cancer cells. Transl Oncol 2018, 11, 786-793.
17. De Mariano, M.; Gallesio, R.; Chierici, M.; Furlanello, C.; Conte, M.; Garaventa, A.; Croce, M.; Ferrini, S.; Tonini, G.P.; Longo, L. Identification of galnt14 as a novel neuroblastoma predisposition gene. Oncotarget 2015, 6, 26335-26346.
18. Liang, K.H.; Lin, C.C.; Yeh, C.T. Galnt14 snp as a potential predictor of response to combination chemotherapy using 5-fu, mitoxantrone and cisplatin in advanced hcc. Pharmacogenomics 2011, 12, 1061-1073.
19. Yeh, C.T.; Liang, K.H.; Lin, C.C.; Chang, M.L.; Hsu, C.L.; Hung, C.F. A single nucleotide polymorphism on the galnt14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. Int J Cancer 2014, 134, 1214-1224.
20. Lin, W.R.; Hsu, C.W.; Chen, Y.C.; Chang, M.L.; Liang, K.H.; Huang, Y.H.; Yeh, C.T. Galnt14 genotype, alpha-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. Mol Clin Oncol 2014, 2, 630-640.
21. Liang, K.H.; Yang, P.C.; Yeh, C.T. Genotyping the galnt14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons. Oncol Lett 2014, 8, 2215-2220.
22. Liang, K.H.; Lin, C.L.; Chen, S.F.; Chiu, C.W.; Yang, P.C.; Chang, M.L.; Lin, C.C.; Sung, K.F.; Yeh, C.; Hung, C.F., et al. Galnt14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics 2016, 17, 353-366.
23. Lin, W.R.; Hsu, C.W.; Yeh, C.S.; Chen, Y.C.; Chang, M.L.; Liang, K.H.; Lin, C.C.; Chu, Y.D.; Yeh, C.T. Combinations of single nucleotide polymorphisms wwox-rs13338697, galnt14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2018, 14, e54-e63.
24. Lin, C.C.; Hsu, C.W.; Chen, Y.C.; Chang, M.L.; Liang, K.H.; Lai, M.W.; Lin, C.L.; Chien, R.N.; Lin, K.H.; Yeh, C.T. A galnt14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: Systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J 2019.
25. Honing, J.; Smit, J.K.; Muijs, C.T.; Burgerhof, J.G.; de Groot, J.W.; Paardekooper, G.; Muller, K.; Woutersen, D.; Legdeur, M.J.; Fiets, W.E., et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014, 25, 638-643.
26. Stahl, M.; Budach, W.; Meyer, H.J.; Cervantes, A.; Group, E.G.W. Esophageal cancer: Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21 Suppl 5, v46-49.
27. Tsou, Y.K.; Liang, K.H.; Lin, W.R.; Chang, H.K.; Tseng, C.K.; Yeh, C.T. Galnt14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncotarget 2017, 8, 29151-29160.
28. Piessen, G.; Messager, M.; Leteurtre, E.; Jean-Pierre, T.; Mariette, C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009, 250, 878-887.
29. Chen, T.H.; Lin, W.R.; Lee, C.; Chiu, C.T.; Hsu, J.T.; Yeh, T.S.; Lin, K.H.; Le, P.H.; Yeh, C.T. Prognostic stratification of advanced gastric signet ring cell carcinoma by clinicopathological factors and galnt14 genotype. J Cancer 2018, 9, 3540-3547.
30. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350, 2343-2351.
31. Kuebler, J.P.; Wieand, H.S.; O'Connell, M.J.; Smith, R.E.; Colangelo, L.H.; Yothers, G.; Petrelli, N.J.; Findlay, M.P.; Seay, T.E.; Atkins, J.N., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage ii and iii colon cancer: Results from nsabp c-07. J Clin Oncol 2007, 25, 2198-2204.
32. Sanoff, H.K.; Carpenter, W.R.; Martin, C.F.; Sargent, D.J.; Meyerhardt, J.A.; Sturmer, T.; Fine, J.P.; Weeks, J.; Niland, J.; Kahn, K.L., et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage iii colon cancer. J Natl Cancer Inst 2012, 104, 211-227.
33. Lin, W.R.; Chiang, J.M.; Liang, K.H.; Lim, S.N.; Lai, M.W.; Tsou, Y.K.; Hsieh, T.Y.; Hsu, C.K.; Yeh, C.T. Galnt14 genotype predicts postoperative outcome of stage iii colorectal cancer with oxaliplatin as adjuvant chemotherapy. Medicine (Baltimore) 2016, 95, e3487.
34. Hasan, S.; Jacob, R.; Manne, U.; Paluri, R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019, 13, 410.
35. Chiang, C.C.; Yeh, C.T.; Hwang, T.L.; Chu, Y.D.; Lim, S.N.; Chen, C.W.; Kuo, C.J.; Le, P.H.; Chen, T.H.; Lin, W.R. The galnt14 genotype predicts postoperative outcome of pancreatic ductal adenocarcinoma. J Clin Med 2019, 8.
36. Blechacz, B.; Gores, G.J. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48, 308-321.
37. Liang, K.H.; Yeh, T.S.; Wu, R.C.; Yeh, C.N.; Yeh, C.T. Galnt14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. Oncol Lett 2017, 13, 4215-4223.
38. Wu, C.; Guo, X.; Wang, W.; Wang, Y.; Shan, Y.; Zhang, B.; Song, W.; Ma, S.; Ge, J.; Deng, H., et al. N-acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer 2010, 10, 123.
39. Zuo, T.; Shan, J.; Liu, Y.; Xie, R.; Yu, X.; Wu, C. Efemp2 mediates galnt14-dependent breast cancer cell invasion. Transl Oncol 2018, 11, 346-352.
40. Wu, J.; Chen, X.; Bao, Q.; Duan, R.; Jin, Y.; Shui, Y.; Yao, B.; Lu, X.; Wang, Y.; Cui, H., et al. Osterix decreases the chemosensitivity of breast cancer cells by upregulating galnt14. Cell Physiol Biochem 2017, 44, 998-1010.
41. Sheta, R.; Bachvarova, M.; Plante, M.; Gregoire, J.; Renaud, M.C.; Sebastianelli, A.; Popa, I.; Bachvarov, D. Altered expression of different galnactransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. Int J Oncol 2017, 51, 1887-1897.
42. Yang, J.; Li, G.; Zhang, K. Mir-125a regulates ovarian cancer proliferation and invasion by repressing galnt14 expression. Biomed Pharmacother 2016, 80, 381-387.
43. Hillman, J.C.; Pugacheva, E.M.; Barger, C.J.; Sribenja, S.; Rosario, S.; Albahrani, M.; Truskinovsky, A.M.; Stablewski, A.; Liu, S.; Loukinov, D.I., et al. Boris expression in ovarian cancer precursor cells alters the ctcf cistrome and enhances invasiveness through galnt14. Mol Cancer Res 2019, 17, 2051-2062.
44. Lee, E.S.; Son, D.S.; Kim, S.H.; Lee, J.; Jo, J.; Han, J.; Kim, H.; Lee, H.J.; Choi, H.Y.; Jung, Y., et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008, 14, 7397-7404.
45. Stern, H.M.; Padilla, M.; Wagner, K.; Amler, L.; Ashkenazi, A. Development of immunohistochemistry assays to assess galnt14 and fut3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 2010, 16, 1587-1596.